A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo

Cytotherapy

Volumn 8, Issue 4, 2006, Pages 415-423

  Yan, Z ^a,b   Zhao, N ^a,b   Wang, Z ^a,b   Li, B ^a,b   Bao, C ^a,b   Shi, J ^a,b   Han, W ^a,b   Zhang, Y ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Cancer Biology   (China)

Author keywords

Anti tumor activity; DNA recombination; Mutation; Purification; Tumor necrosis factor

Indexed keywords

AMINO ACID; ARGININE; ASPARTIC ACID; CYCLOPHOSPHAMIDE; LEUCINE; LYSINE; MUTANT PROTEIN; PHENYLALANINE; PROLINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SERINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL LYSATE; CHILL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG DOSE REGIMEN; EDEMA; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; FEVER; FIBROBLAST; GEL PERMEATION CHROMATOGRAPHY; GENE DELETION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; MOUSE; MUTANT; NONHUMAN; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRECIPITATION; PRIORITY JOURNAL; PROKARYOTE; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SUPERNATANT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747727615     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240600845278     Document Type: Article

References (34)

1. Carswell, EA and Old, LJ and Kassel, RL and (1975) An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci USA, 72, pp. 3666-70.
2. Old, LJ. (1985) Tumor necrosis factor (TNF) Science, 230, pp. 630-2.
3. Watanabe, N and Niitsu, Y and Umeno, H and (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice Cancer Res, 48, pp. 2179-83.
4. Folli, S and Pelegrin, A and Chalandon, Y and (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability Int J Cancer, 53, pp. 829-36.
5. Hagen, TL and Eggermont, AM. (2003) Solid tumor therapy: Manipulation of the vasculature with TNF Technol Cancer Res Treat, 2, pp. 195-203.
6. Haranaka, K and Satomi, N and Sakurai, A. (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice Int J Cancer, 34, pp. 263-7.
7. Sasaki, Y and Kanzawa, F and Takahashi, H and (1987) In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay Invest New Drugs, 5, pp. 353-9.
8. Blick, M and Sherwin, SA and Rosenblum, M and Gutterman, J. (1987) Phase I study of recombinant tumor necrosis factor in cancer patients Cancer Res, 47, pp. 2986-9.
9. Kimura, K and Taguchi, T and Urushizaki, I and (1987) Phase I study of recombinant human tumor necrosis factor Cancer Chemother Pharmacol, 20, pp. 223-9.
10. Kemeny, N and Childs, B and Larchian, W and (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma Cancer, 66, pp. 659-63.
11. Lejeune, FJ and Ruegg, C and Lienard, D. (1998) Clinical applications of TNF-α in cancer Curr Opin Immunol, 10, pp. 573-80.
12. Jones, AL and Selby, P. (1989) Tumour necrosis factor: Clinical relevance Cancer Surv, 8, pp. 817-36.
13. Wiedenmann, B and Reichardt, P and Rath, U and (1989) Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas J Cancer Res Clin Oncol, 115, pp. 189-92.
14. Bartsch, HH and Pfizenmaier, K and Schroder, M and Nagel, GA. (1989) Systemic versus local therapy with recombinant tumor necrosis factor-α (r-TNF-α) in patients with advanced tumors Oncology, 12, pp. 136-41.
15. Mavligit, GM and Zukiwski, AA and Charnsangavej, C and (1992) Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases Cancer, 69, pp. 557-61.
16. Nakamura A, Kato A, Masegi T. A novel recombinant tumor necrosis factor-α mutant with increased anti-tumor activity and lower toxicity. Int J Cancer 19914;8:744-8.
17. Ostade, XV and Vandenabeele, P and Everaerdt, B and (1993) Human TNF mutants with selective activity on the p55 receptor Nature, 361, pp. 266-9.
18. Reed, C and Fu, ZQ and Wu, J and (1997) Crystal structure of TNF-α mutant R31D with greater affinity for receptor R1 compared with R2 Protein Eng, 10, pp. 1101-07.
19. Shin, NK and Lee, I and Chang, SG and Shin, HC. (1998) A novel tumor necrosis factor-α mutant with significantly enhanced cytotoxicity and receptor binding affinity Biochem Mol Biol Int, 44, pp. 1075-82.
20. Cha, SS and Kim, JS and Cho, HS and (1998) High resolution crystal structure of a human tumor necrosis factor-α mutant with low systemic toxicity J Biol Chem, 273, pp. 2153-60.
21. Kuroda, K and Miyata, K and Fujita, F and (2000) Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice Cancer Lett, 159, pp. 33-41.
22. Zhang, ZQ and Yao, LH and Hou, YD. (1990) Construction and application of a high level expression vector containing PRPL promoter Chinese J Virol, 6, pp. 111-16.
23. Yan, Z and Zhang, YQ and Li, M and Cheng, CQ. (2001) Fermentation research of new type recombinant human tumor necrosis factor α Chinese J Biochem Pharm, 22, pp. 64-7.
24. Lowry, OH and Rosebrough, NJ and Farr, AL and Randall, RJ. (1951) Protein measurement with the Folin phenol reagent J Biol Chem, 193, pp. 265-75.
25. Laemmli, UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature, 227, pp. 680-5.
26. Fransen, L and Van der Heyden, J and Ruysschaert, R and Fiers, W. (1986) Recombinant tumor necrosis factor: Its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines Eur J Cancer Clin Oncol, 22, pp. 419-26.
27. Beyaert, R and Fiers, W. (1994) Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not FEBS Lett, 340, pp. 9-16.
28. Liu, ZG and Han, J. (2001) Cellular responses to tumor necrosis factor Curr Issues Mol Biol, 3, pp. 79-90.
29. Lu, Y and Yamauchi, N and Koshita, Y and (2001) Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule Gene Ther, 8, pp. 499-507.
30. Curnis, F and Sacchi, A and Corti, A. (2002) Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration J Clin Invest, 110, pp. 475-82.
31. Kamijo, R and Takeda, K and Nagumo, M and (1989) Induction of differentiation of human monoblastic and myeloblastic leukemia cell lines by TNF muteins Biochem Biophys Res Commun, 160, pp. 820-7.
32. Hagen, TL and Eggermont, AM. (2004) Tumor vascular therapy with TNF: critical review on animal models Methods Mol Med, 98, pp. 227-46.
33. Curnis, F and Gasparri, A and Sacchi, A and (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity Cancer Res, 64, pp. 565-71.
34. Lejeune, FJ. (2002) Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability J Clin Invest, 110, pp. 433-5.